文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

血必净治疗脓毒症患者

Xuebijing in the treatment of patients with sepsis.
PubMed 文献 · Am J Emerg Med · 2016-11-03
一句话结论血必净注射液联合常规治疗可降低脓毒症患者28天死亡率(RR 0.51,95%CI 0.44-0.59),但作者认为需更多高质量多中心随机对照研究证实。

该Meta分析检索PubMed、Cochrane、Embase、万方、CNKI、维普数据库至2016年6月,纳入49项随机病例对照研究,共2023例血必净组和1861例对照组脓毒症患者。与常规治疗相比,血必净注射液可显著降低APACHE-II评分、PCT、WBC、CRP、NEU和T0,并显著降低28天死亡率(RR 0.51,95%CI 0.44-0.59)。作者结论为血必净注射液对脓毒症有显著临床疗效,但需要更多随机、大样本、高质量、多中心研究证实其确切疗效。

要点

  • 血必净组28天死亡率显著低于对照组(RR 0.51,95%CI 0.44-0.59)。
  • 血必净组APACHE-II评分较对照组显著降低(WMD -3.70,95%CI -4.31至-3.09)。
  • 血必净组PCT较对照组显著降低(WMD -1.26 μg/L,95%CI -1.63至-0.88 μg/L)。
  • 血必净组CRP较对照组显著降低(WMD -24.38 mg/L,95%CI -30.49至-18.26 mg/L)。
  • 作者认为需更多随机、大样本、高质量、多中心研究证实血必净注射液的确切疗效。

适用人群与场景

  • 脓毒症患者,纳入49项随机病例对照研究,血必净组2023例,对照组1861例。

处置流程与药物剂量

  • 血必净注射液联合常规治疗用于脓毒症患者;原文未给出具体剂量、给药途径、频次或疗程。

研究设计与关键结果

  • 研究类型为Meta分析,纳入49项随机病例对照研究,血必净组2023例、对照组1861例。
  • 与常规治疗相比,血必净注射液显著降低APACHE-II评分(WMD -3.70,95%CI -4.31至-3.09)、PCT(WMD -1.26 μg/L,95%CI -1.63至-0.88 μg/L)、WBC(WMD -1.48×10^9/L,95%CI -2.03至-0.94×10^9/L)、CRP(WMD -24.38 mg/L,95%CI -30.49至-18.26 mg/L)、NEU(WMD -4.68,95%CI -8.32至-1.04)和T0(WMD -0.50,95%CI -0.92至-0.07)。
  • 血必净组28天死亡率显著低于对照组(RR 0.51,95%CI 0.44-0.59)。

证据类型、等级与局限

  • 证据类型为Meta分析,纳入49项随机病例对照研究,采用Jadad量表评价文献质量。
  • 局限:作者指出需要更多随机、大样本、高质量、多中心研究证实血必净注射液的确切疗效。

对床旁实践的改变

  • 作者认为血必净注射液对脓毒症患者有显著临床疗效,但需更多随机、大样本、高质量、多中心研究证实其确切疗效。
  • 原文未给出血必净注射液的具体剂量、给药途径、频次或疗程,无法据此形成床旁用药方案。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: There are more than 18 million patients diagnosed with sepsis every year. In China, Xuebijing (XBJ) injection is a traditional medicine that is widely used in the treatment of sepsis. However, the efficacy of XBJ in treatment of randomized controlled trials (RCTs) remains unclear. This meta-analysis was to evaluate the clinical efficacy of XBJ based on randomized case-control studies.

METHODS: PubMed, Cochrane, Embase, Wanfang, CNKI, and WeiPu (VIP) databases were searched to identify all the relative randomized case-control. The latest research was done in June, 2016. Relative risks (RR), weighted mean difference (WMD) along with 95% confidence interval (95%CI) were used to analyze the main outcomes. Statistical analysis was performed using STATA 10.0 (TX, USA). The qualities of the involved articles were accessed by the Jadad scale.

RESULTS: Forty-nine randomized case-control studies met the inclusion and exclusion criteria, with 1861 patients in the control group and 2023 patients in the XBJ group. Compared with the conventional therapy, XBJ injection could significantly reduce the APACHE-IIscore (WMD: -3.70, 95%CI: -4.31-[-3.09]), PCT (WMD: -1.26μg/L, 95%CI: -1.63μg/L-[-0.88μg/L]), WBC (WMD: -1.48×109/L, 95%CI: -2.03×109/L-[-0.94×109/L]), CRP (WMD: -24.38mg/L, 95%CI:-30.49mg/L-[-18.26mg/L]), NEU (WMD: -4.68, 95%CI: -8.32-[-1.04]), T0(WMD: -0.50, 95%CI: -0.92-[-0.07]). The 28-day mortality of the XBJ group was significantly lower than the control group (RR: 0.51; 95%CI: 0.44-0.59).

CONCLUSION: XBJ injection has a significant clinical efficacy in the therapy of patients with sepsis. However, there is a need for more randomized, lager-sample size, high-quality, and multicenter studies to confirm the extract efficacy of XBJ injection.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Shi H, Hong Y, Qian J, et al. Xuebijing in the treatment of patients with sepsis. Am J Emerg Med. 2016. PMID: 27852528. doi:10.1016/j.ajem.2016.11.007

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。